What it's for (Indications)
- Hydralazine is a direct-acting vasodilator primarily indicated for the management of moderate to severe essential hypertension, often used in combination with other antihypertensive agents, such as beta-blockers and diuretics, to mitigate reflex sympathetic activation and fluid retention.
- It can also be utilized in hypertensive emergencies, typically administered parenterally, when rapid blood pressure reduction is clinically necessary.
- Additionally, hydralazine, particularly in conjunction with isosorbide dinitrate, plays a critical role in the treatment of heart failure with reduced ejection fraction, especially in African American patients, based on evidence from trials like A-HeFT.
- Its use extends to the treatment of pre-eclampsia and eclampsia in obstetric settings to manage severe hypertension, making it a versatile agent for various acute and chronic hypertensive conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of hydralazine must be individualized based on the patient's response and tolerance, typically starting with low doses and gradually titrating upwards. For oral administration in adults, an initial dose of 10 mg four times daily is common, which may be increased to 25 mg four times daily after two to four days, and then to a maintenance dose of 50 mg four times daily as needed. The usual maximum daily oral dose is 200 mg, though some patients with severe hypertension refractory to other treatments may require up to 300-400 mg daily in divided doses under close medical supervision. For intravenous or intramuscular administration in hypertensive emergencies, an initial dose of 10-20 mg is typical, which can be repeated as necessary, generally not exceeding 20-40 mg per dose, with careful monitoring of blood pressure and heart rate to avoid precipitous drops. Dosage adjustments are often required in patients with renal impairment. |
Safety & Warnings
Common Side Effects
- Common side effects associated with hydralazine therapy often result from its vasodilatory action and include headache, nausea, vomiting, diarrhea, palpitations, and tachycardia.
- Reflex sympathetic stimulation can also precipitate angina pectoris, especially in patients with underlying coronary artery disease.
- More serious adverse reactions, although less frequent, can include a dose-dependent lupus-like syndrome, characterized by arthralgia, myalgia, fever, skin rash, and serological abnormalities; this syndrome typically resolves upon drug discontinuation.
- Other severe but rare side effects encompass peripheral neuritis (which may be reversed with pyridoxine), blood dyscrasias such as agranulocytosis, leukopenia, thrombocytopenia, and aplastic anemia, as well as hypersensitivity reactions, renal damage, and hepatitis.
- Fluid retention and edema are also potential complications due to activation of the renin-angiotensin-aldosterone system.
Serious Warnings
- Black Box Warning: While hydralazine does not carry a formal FDA Black Box Warning, several serious safety concerns warrant significant caution and careful patient monitoring, effectively functioning as critical warnings. The most prominent is the potential for developing a dose-dependent, reversible lupus-like syndrome (drug-induced lupus erythematosus). This syndrome, characterized by arthralgia, myalgia, fever, skin rash, and positive antinuclear antibody (ANA) titers, occurs more frequently with higher doses (typically >200 mg/day) and prolonged treatment. Patients should be regularly screened for symptoms and, if developed, the drug should be discontinued. Additionally, hydralazine can precipitate or worsen angina pectoris and myocardial infarction, particularly in patients with underlying coronary artery disease or those prone to reflex tachycardia. Due to its potent vasodilatory effects, careful titration and concurrent use of beta-blockers may be necessary to attenuate sympathetic activation and minimize cardiovascular risk. Blood dyscrasias and peripheral neuritis are other serious but rare adverse events requiring vigilance.
- Hydralazine should be used with extreme caution in patients with known or suspected coronary artery disease, as its potent vasodilatory effects can induce reflex tachycardia and increase myocardial oxygen demand, potentially exacerbating angina or precipitating myocardial infarction.
- The development of a systemic lupus erythematosus (SLE)-like syndrome is a significant concern, particularly with higher doses (e.
- g.
- , above 200 mg/day) and prolonged therapy; patients should be monitored for clinical signs and symptoms and appropriate laboratory tests.
- In patients with renal impairment, reduced dosages may be necessary to prevent accumulation and toxicity.
- Abrupt discontinuation of hydralazine can lead to rebound hypertension and withdrawal symptoms; therefore, the drug should be tapered gradually when therapy is ceased.
- Sodium and fluid retention may occur, often requiring co-administration of diuretics.
- Peripheral neuritis, thought to be related to pyridoxine deficiency, can develop, and pyridoxine supplementation may be considered.
How it Works (Mechanism of Action)
Hydralazine acts as a direct-acting peripheral vasodilator, exerting its primary effect by relaxing arterial smooth muscle. This leads to a reduction in peripheral vascular resistance, subsequently decreasing arterial blood pressure and cardiac afterload. While the precise molecular mechanism is not fully elucidated, it is believed to involve the release of nitric oxide (NO) from endothelial cells, or a direct action on vascular smooth muscle cells, which then stimulates guanylate cyclase, leading to increased intracellular cyclic guanosine monophosphate (cGMP). Elevated cGMP levels promote smooth muscle relaxation through mechanisms involving reduced intracellular calcium. Hydralazine's vasodilatory action is more pronounced on arterioles than on venules, resulting in a reduction in systemic vascular resistance without significant changes in venous capacitance. This arteriolar vasodilation improves forward flow and reduces the workload on the heart.
Commercial Brands (Alternatives)
No other brands found for this formula.